Libromide 325 mg tablets for dogs
Libromide 325 mg tablets for dogs
Authorised
- Potassium bromide
Product identification
Medicine name:
Libromide 325 mg tablets for dogs
Libromide 325 mg Tablet
Libromide 325 mg Comprimé
Libromide 325 mg Tablette
Active substance:
- Potassium bromide
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Potassium bromide325.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QN05CM11
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Package description:
- Pack size 100: White, opaque polypropylene cylindrical pots, with white, opaque polyethylene child resistant or tamper evident lids.
- Pack size 500: White, opaque polypropylene cylindrical pots, with white, opaque polyethylene child resistant or tamper evident lids.
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Dechra Regulatory B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Genera d.d.
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V404047
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0507/001
Concerned member states:
-
Austria
-
Belgium
-
Czechia
-
Denmark
-
Finland
-
France
-
Germany
-
Hungary
-
Italy
-
Luxembourg
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Labelling
This document does not exist in this language (English). You can find it
in another language below.
